Herne and Cioffi bring decades of commercial and clinical operating experience to the MedAvante-ProPhase leadership team, which is primarily composed of clinicians and scientists. "With the support of WCG - and the leadership of a world-class team of experts - we are confident in our ability to deliver smarter, faster clinical trials that will ultimately result in better treatment options for patients."
"MedAvante-ProPhase is poised to take the next steps in its growth, and to accelerate the next phase of innovation for its clients and the industry," said Jeffrey Litwin, MD, CEO, MedAvante-ProPhase.
#Medavante prophase trial#
Through the power of the combined MedAvante-ProPhase organization, clients have access to the largest global team of clinicians, the leading eCOA technology platform, and a suite of complementary solutions to maximize trial efficiency. Individually, both companies have a track record of helping clients to optimize the selection, use, and analysis of behavioral endpoints to mitigate trial risk and increase the likelihood of a study's success. WCG acquired MedAvante and ProPhase in May, 2017, bringing together over 180 clinicians, scientists and technologists who specialize in the field of eCOA.
"Because their outcomes rely on subjective assessment, we believe that continued innovation in signal detection is the key to unlocking new treatments in these therapeutic areas." Deieso, PhD, Chairman and Chief Executive Officer (CEO), WCG. "Despite the large and growing unmet medical need, clinical trials in CNS and behavioral health progress more slowly – and attract less funding – than other therapeutic areas," said Donald A. Herne and Cioffi are tasked with expanding MedAvante-ProPhase's already formidable portfolio of services and technologies, which improve the quality of clinical trial data collection and analysis in the fields of CNS and mental health. 15, 2017 /PRNewswire/ - WIRB-Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced today that industry experts Steven Herne and Michael Cioffi have joined the leadership of MedAvante-ProPhase, the Group's electronic clinical outcomes assessment (eCOA) arm.
0 kommentar(er)
